Cabio Biotech (Wuhan)（688089）株式概要カビオ・バイオテック（武漢）有限公司は、国内外の乳児用粉ミルクや健康食品メーカー向けに、アラキドン酸、ドコサヘキサエン酸、ベータカロチンを開発、生産、販売している。 詳細688089 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績1/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より72.1%で取引されている リスク分析利益率(13.2%)は昨年より低い(24.4%) 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る688089 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,582 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,582 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥10.2528.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0713m2016201920222025202620282031Revenue CN¥712.7mEarnings CN¥94.0mAdvancedSet Fair ValueView all narrativesCabio Biotech (Wuhan) Co., Ltd. 競合他社Sunlour PigmentSymbol: SZSE:301036Market cap: CN¥1.9bZhejiang Wanfeng ChemicalLtdSymbol: SHSE:603172Market cap: CN¥2.0bAnhui Hyea AromasSymbol: SZSE:300886Market cap: CN¥1.5bZhe Jiang Dayang Biotech GroupSymbol: SZSE:003017Market cap: CN¥2.0b価格と性能株価の高値、安値、推移の概要Cabio Biotech (Wuhan)過去の株価現在の株価CN¥10.2552週高値CN¥31.1352週安値CN¥9.93ベータ0.271ヶ月の変化-12.02%3ヶ月変化-32.03%1年変化-62.59%3年間の変化-53.15%5年間の変化n/aIPOからの変化-70.87%最新ニュースお知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei ChinaBoard Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.最新情報をもっと見るRecent updatesお知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei ChinaBoard Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • May 08Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei Chinaお知らせ • Mar 28Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Jan 25Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.お知らせ • Dec 27Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥25.10, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 30% over the past year.Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.098 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥126.3m (flat on 3Q 2023). Net income: CN¥16.0m (down 37% from 3Q 2023). Profit margin: 13% (down from 20% in 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥18.54, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 1.7% over the past year.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥17.55, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 9.0% over the past year.New Risk • Sep 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥143.8m (up 30% from 2Q 2023). Net income: CN¥43.6m (up 112% from 2Q 2023). Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Aug 28Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 20 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.06, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 25% over the past year.お知らせ • Jun 28Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • May 18Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei ChinaValuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 34%After last week's 34% share price gain to CN¥19.65, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 11% over the past year.Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.086 in 1Q 2023). Revenue: CN¥117.0m (up 33% from 1Q 2023). Net income: CN¥24.3m (up 70% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024Reported Earnings • Feb 26Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.39 in FY 2022)Full year 2023 results: EPS: CN¥0.54 (up from CN¥0.39 in FY 2022). Revenue: CN¥445.5m (up 2.8% from FY 2022). Net income: CN¥91.5m (up 42% from FY 2022). Profit margin: 21% (up from 15% in FY 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China.New Risk • Feb 25New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (9.7% net profit margin).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in China.お知らせ • Dec 29Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥111.0m (up 16% from 2Q 2022). Net income: CN¥20.5m (down 23% from 2Q 2022). Profit margin: 19% (down from 28% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • May 10Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023CABIO Biotech (Wuhan) Co., Ltd. announced on May 9 to 11, 2023, the company participates in the three-day Vitafoods Europe held in Geneva, Switzerland. The company showcases three new ingredients — HMOs, Salecan® ß-glucan and elastin — as well as its already well-known ARA, algal oil DHA, ß-Carotene and sialic acid (SA) during the exhibition. HMOs, human milk oligosaccharides in full, are the significant components of breast milk and play an essential part in promoting infant brain development, maintaining intestinal microecological balance, building resistance to bacteria and viruses, and improving immunoregulation. Adult ingestion of HMOs also enhances the quality of life by contributing positively to intestinal microbiota while likely improving severe symptoms of irritable bowel syndrome (IBS). Salecan® ß-glucan is a novel water-soluble ß-glucan generated from a patented strain using the fermentation process. Approved by both FDA-GRAS and Chinese FDA New Food Ingredient Accreditation, Salecan® ß-glucan is applied extensively in food & drinks, foods for special dietary uses (FSDUs) and dietary supplements to enhance immunity, regulate intestinal microbiota, repair intestinal mucosae and improve blood lipid and sugar levels. Elastin is the main component of the elastic fiber in the skin. It works together with collagen and hyaluronic acid (HA) to maintain skin elasticity. Elastin extracted from the horse nuchal ligament contains large quantities of desmosine and isodesmosine that can smooth wrinkles, hydrate, whiten and repair the skin, plump the breasts, and lift the hips; therefore it's widely applied in food, drinks, cosmetics and skincare. As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health. Remaining steadfast in basic research, CABIO makes every effort to explore synthetic biology and biomedicine by mining the limitless potential consistently to offer quality ingredients and ready-to-market solutions to customers worldwide.Valuation Update With 7 Day Price Move • May 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥31.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Apr 14Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in FY 2021)Full year 2022 results: EPS: CN¥0.54 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥64.4m (down 50% from FY 2021). Profit margin: 15% (down from 37% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Board Change • Mar 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元688089CN ChemicalsCN 市場7D-7.5%-6.8%-4.7%1Y-62.6%24.2%10.6%株主還元を見る業界別リターン: 688089過去 1 年間で24.2 % の収益を上げたCN Chemicals業界を下回りました。リターン対市場: 688089は、過去 1 年間で10.6 % のリターンを上げたCN市場を下回りました。価格変動Is 688089's price volatile compared to industry and market?688089 volatility688089 Average Weekly Movement5.5%Chemicals Industry Average Movement7.7%Market Average Movement7.3%10% most volatile stocks in CN Market12.3%10% least volatile stocks in CN Market4.3%安定した株価: 688089 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 688089の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1999595Dewei Yiwww.cabio.cnCabio Biotech (Wuhan) Co., Ltd.は、国内外の乳児用粉ミルク、健康食品メーカー向けにアラキドン酸、ドコサヘキサエン酸、ベータカロチンを開発、生産、販売している。同社の製品は、乳児用調製粉乳食品、健康食品、栄養補助食品などの特殊医療用分野、ペット用栄養食品、経済飼料、パーソナルケア、化粧品などの分野で使用されている。同社は1999年に設立され、中華人民共和国の武漢に本社を置いている。もっと見るCabio Biotech (Wuhan) Co., Ltd. 基礎のまとめCabio Biotech (Wuhan) の収益と売上を時価総額と比較するとどうか。688089 基礎統計学時価総額CN¥1.69b収益（TTM）CN¥55.16m売上高(TTM)CN¥418.18m30.6xPER（株価収益率4.0xP/Sレシオ688089 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計688089 損益計算書（TTM）収益CN¥418.18m売上原価CN¥254.87m売上総利益CN¥163.31mその他の費用CN¥108.15m収益CN¥55.16m直近の収益報告Mar 31, 2026次回決算日Aug 22, 2026一株当たり利益（EPS）0.34グロス・マージン39.05%純利益率13.19%有利子負債／自己資本比率12.9%688089 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 20:52終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cabio Biotech (Wuhan) Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Li WuTianfeng Securities Brokerage Co., LtdJinsong FanZhongtai Securities Co. Ltd.
お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei China
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.
お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei China
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.
お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • May 08Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China
お知らせ • Mar 28Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Jan 25Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.
お知らせ • Dec 27Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥25.10, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 30% over the past year.
Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.098 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥126.3m (flat on 3Q 2023). Net income: CN¥16.0m (down 37% from 3Q 2023). Profit margin: 13% (down from 20% in 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥18.54, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 1.7% over the past year.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.
お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥17.55, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 9.0% over the past year.
New Risk • Sep 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥143.8m (up 30% from 2Q 2023). Net income: CN¥43.6m (up 112% from 2Q 2023). Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Aug 28Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 20 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.
New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.06, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 25% over the past year.
お知らせ • Jun 28Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • May 18Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 34%After last week's 34% share price gain to CN¥19.65, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 11% over the past year.
Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.086 in 1Q 2023). Revenue: CN¥117.0m (up 33% from 1Q 2023). Net income: CN¥24.3m (up 70% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024
Reported Earnings • Feb 26Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.39 in FY 2022)Full year 2023 results: EPS: CN¥0.54 (up from CN¥0.39 in FY 2022). Revenue: CN¥445.5m (up 2.8% from FY 2022). Net income: CN¥91.5m (up 42% from FY 2022). Profit margin: 21% (up from 15% in FY 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China.
New Risk • Feb 25New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (9.7% net profit margin).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in China.
お知らせ • Dec 29Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024
Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥111.0m (up 16% from 2Q 2022). Net income: CN¥20.5m (down 23% from 2Q 2022). Profit margin: 19% (down from 28% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • May 10Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023CABIO Biotech (Wuhan) Co., Ltd. announced on May 9 to 11, 2023, the company participates in the three-day Vitafoods Europe held in Geneva, Switzerland. The company showcases three new ingredients — HMOs, Salecan® ß-glucan and elastin — as well as its already well-known ARA, algal oil DHA, ß-Carotene and sialic acid (SA) during the exhibition. HMOs, human milk oligosaccharides in full, are the significant components of breast milk and play an essential part in promoting infant brain development, maintaining intestinal microecological balance, building resistance to bacteria and viruses, and improving immunoregulation. Adult ingestion of HMOs also enhances the quality of life by contributing positively to intestinal microbiota while likely improving severe symptoms of irritable bowel syndrome (IBS). Salecan® ß-glucan is a novel water-soluble ß-glucan generated from a patented strain using the fermentation process. Approved by both FDA-GRAS and Chinese FDA New Food Ingredient Accreditation, Salecan® ß-glucan is applied extensively in food & drinks, foods for special dietary uses (FSDUs) and dietary supplements to enhance immunity, regulate intestinal microbiota, repair intestinal mucosae and improve blood lipid and sugar levels. Elastin is the main component of the elastic fiber in the skin. It works together with collagen and hyaluronic acid (HA) to maintain skin elasticity. Elastin extracted from the horse nuchal ligament contains large quantities of desmosine and isodesmosine that can smooth wrinkles, hydrate, whiten and repair the skin, plump the breasts, and lift the hips; therefore it's widely applied in food, drinks, cosmetics and skincare. As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health. Remaining steadfast in basic research, CABIO makes every effort to explore synthetic biology and biomedicine by mining the limitless potential consistently to offer quality ingredients and ready-to-market solutions to customers worldwide.
Valuation Update With 7 Day Price Move • May 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥31.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Apr 14Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in FY 2021)Full year 2022 results: EPS: CN¥0.54 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥64.4m (down 50% from FY 2021). Profit margin: 15% (down from 37% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Board Change • Mar 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
